Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2939-2944

  Kozuka, Teruhiko ^a   Kiura, Katsuyuki ^a   Katayama, Hideki ^a   Fujii, Nobuharu ^a   Ishimaru, Fumihiko ^a   Ikeda, Kazuma ^a   Ueoka, Hiroshi ^a   Hamasaki, Shuuji ^a   Yoshino, Tadashi ^b   Kashihara, Yoshio ^a   Date, Hiroshi ^a   Tanimoto, Mitsune ^a,b   Harada, Mine ^c  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Autologous peripheral blood stem cell transplantation; Malignant fibrous histiocytoma; Malignant hemangiopericytoma; Soft tissue sarcoma; Tandem high dose chemotherapy

Indexed keywords

CARBOPLATIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ABDOMINAL TUMOR; ADULT; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER DYSFUNCTION; LUNG METASTASIS; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; QUALITY OF LIFE; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IFOSFAMIDE; MALE; NEOPLASM RECURRENCE, LOCAL; RETROPERITONEAL NEOPLASMS; SARCOMA;

EID: 0036765988     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17: 150-7, 1999.
2. Edmonson JH, Ryan LM, Blum RH et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-75, 1993.
3. Antman K, Crowley J, Balcerzak SP et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-85, 1993.
4. Santoro A, Tursz T, Mouridsen H et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-45, 1995.
5. Blay JY, Bouhour D, Ray-Coquard I et al: High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18: 3643-50, 2000.
6. Dumontet C, Biron P, Bouffet E et al: High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant 10: 405-8, 1992.
7. Mesia R, Sola C, Lopez Pousa A et al: High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas. Rev Clin Esp 194: 960-5, 1994.
8. Hermanek P, Scheibe O, Spiessl B et al: TNM classification of malignant tumors: a new 1987 edition. Pathologe 8: 137, 1987.
9. Coindre JM, Trojani M, Contesso G et al: Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58: 306-9, 1986.
10. Reichardt P, Tilgner J, Hohenberger P et al: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 16: 1438-43, 1998.
11. Fields KK, Elfenbein GJ, Perkins JB et al: High-dose ifosfamide / carboplatin etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. Semin Oncol 21: 86-92, 1994.
12. Oken MM, Creech RH, Tormey DC et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-55, 1982.
13. Shipp MA, Abeloff MD, Antman KH et al: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 17: 423-9, 1999.
14. Philip T, Guglielmi C, Hagenbeek A et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-5, 1995.
15. Haioun C, Lepage E, Gisselbrecht C et al: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1131-7, 1997.
16. Haioun C, Lepage E, Gisselbrecht C et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18: 3025-30, 2000.
17. Attal M, Harousseau JL, Stoppa AM et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335: 91-7, 1996.
18. Barlogie B, Jagannath S, Vesole DH et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89: 789-93, 1997.
19. Barlogie B, Jagannath S, Desikan KR et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93: 55-65, 1999.
20. Bitran JD, Samuels B, Klein L et al: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17: 157-62, 1996.
21. Ayash LJ, Elias A, Schwartz G et al: Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression -free survival by the sequence of high-dose melphalan followed by cyclophosphamide thiotepa, and carboplatin. J Clin Oncol 14: 2984-92, 1996.
22. Margolin BK, Doroshow JH, Ahn C et al: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14: 2631-7, 1996.
23. Lotz JP, Bouleuc C, Andre T et al: Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer 77: 2550-9, 1996.
24. Shapiro CL, Ayash L, Webb IJ et al: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15: 674-83, 1997.
25. Yamane H, Bessho A, Kiura K et al: Double high-dose chemotherapy supported by autologous transplantation of peripheral blood stem cells for treatment of an elderly patient with small-cell lung cancer. Inter Med 38: 892-5, 1999.
26. Elias AD: High-dose therapy for adult soft tissue sarcoma: dose response and survival. Semin Oncol 25: 19-23; discussion 45-8, 1998.